| ²é¿´: 397 | »Ø¸´: 2 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
wqssfj1Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
|
[ÇóÖú]
ÇóÖú·Òë
|
|
|
The MAH must ensure that the system of pharmacovigilance, presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market. in place ÔÚ¾äÖеÄÒâ˼ÊÇʲô£¿ лл£¡ |
» ²ÂÄãϲ»¶
315Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
070300»¯Ñ§Ñ§Ë¶311·ÖÇóµ÷¼Á
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸Äϲý´óѧ£¬085600£¬344·ÖÇóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸ ½ÄÏ´óѧ 085602 »¯¹¤×¨Ë¶ 338·ÖÇóµ÷¼Á
ÒѾÓÐ13È˻ظ´
»¯Ñ§0703-Ò»Ö¾Ô¸211-338·ÖÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
0703µ÷¼Á£¬Ò»Ö¾Ô¸Ìì½ò´óѧ319·Ö
ÒѾÓÐ8È˻ظ´
085602µ÷¼Á ³õÊÔ×Ü·Ö335
ÒѾÓÐ9È˻ظ´
336²ÄÁÏÓ뻯¹¤085600Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ6È˻ظ´
071000ÉúÎïѧµ÷¼Á
ÒѾÓÐ3È˻ظ´
weichin
Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 183
- Ó¦Öú: 18 (СѧÉú)
- ½ð±Ò: 9734.7
- ºì»¨: 17
- Ìû×Ó: 4116
- ÔÚÏß: 345.2Сʱ
- ³æºÅ: 1490943
- ×¢²á: 2011-11-14
- רҵ: ½á¹¹ÌÕ´É

2Â¥2012-03-23 15:32:17
natisean
½ð³æ (СÓÐÃûÆø)
- ·ÒëEPI: 4
- Ó¦Öú: 6 (Ó×¶ùÔ°)
- ½ð±Ò: 1047.1
- ºì»¨: 23
- Ìû×Ó: 104
- ÔÚÏß: 18.9Сʱ
- ³æºÅ: 1261244
- ×¢²á: 2011-04-10
- רҵ: ¾ÛºÏÎï¹²»ìÓ븴ºÏ²ÄÁÏ
3Â¥2012-03-23 16:19:59














»Ø¸´´ËÂ¥
10